Final_Umbrella APS - Accelerating.pdf

U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT

U.S. Embassy Jakarta

Jl. Medan Merdeka Selatan 3-5

Jakarta 10110, Indonesia

USAID.gov

Federal Agency Name: United States Agency for International Development

Funding Opportunity Title: Accelerating Elimination of Tuberculosis (TB) in Indonesia

Announcement Type: Annual Program Statement

Funding Opportunity Number: 72049723APS00001

Federal Assistance Listing Number: 98.001 Foreign Assistance for Programs Overseas

Issuance Date: February 09, 2023

Questions Due Date and Time: February 23, 2023; 10:00 AM, Jakarta Time

Closing Date of this APS: Open until amended to close

Dear Interested Applicants:

This Annual Program Statement (APS) publicizes in accordance with ADS 303.3.5.2(b) as the intention of the United States Government (USG), as represented by the United States Agency for International Development (USAID), Indonesia Mission, to fund one or multiple awards to improve the capacity of the National Tuberculosis Program, local partners, and communities to effectively detect, diagnose, and treat people affected by tuberculosis and provide preventive services to all people in need, while building a sustainable and resilient health system in

Indonesia.

This document is an “umbrella” APS that is not calling for any submission and will not solicit any concept papers nor applications. Prospective applicants will be provided a fair opportunity to develop and submit competitive applications to USAID for potential funding via APS

Addendums under this APS. USAID Indonesia intends to make several assistance awards with

US and local NGOs to assist the Government of Indonesia (GOI) in accelerating achievement toward its 2030 TB elimination.

Following this APS, USAID will issue APS Addendum(s) with more detailed information for applicants to submit their applications. USAID Indonesia may utilize co-creation with prospective applicants during various stages of APS Addendum procurements and applicants

Annual Program Statement Accelerating Elimination of TB in Indonesia may be invited to participate in virtual or in-person events. If/when there is any change related to this APS, the mission will amend this APS accordingly.

Issuance of this APS does not commit USAID to make any awards nor to pay for the costs incurred in the preparation and submission of an application. USAID also reserves the right to reject any application received in response to the APS Addendum(s). USAID reserves the right not to conduct a co-creation and request Full Applications from successful applicants at the concept paper stage, or to conduct co-creation at a later stage of the process. The actual number of awards under this APS is subject to the availability of funds and the viability of applications received. USAID also reserves the right to award multiple awards or no awards at all through this APS.

This APS and the APS Addendum will be posted on www.sam.gov and www.grants.gov. It is the responsibility of the Applicant to regularly check both websites to ensure they have the latest information pertaining to this APS and to ensure that the APS has been received from the internet in its entirety. USAID bears no responsibility for any data errors resulting from transmission or conversion process. If you have difficulty registering on www.grants.gov or accessing the APS document, please contact the Grants.gov Helpdesk at 1-800-518-4726 or via email at support@grants.gov for technical assistance.

Thank you for your interest in USAID programs.

Sincerely, Mohib Ahmed

Supervisory Agreement Officer

Office of Acquisition and Assistance

USAID/Indonesia http://www.sam.gov/ http://www.grants.gov/ mailto:support@grants.gov

TABLE OF CONTENTS

ACRONYMS 4

SECTION A – PROGRAM DESCRIPTION 5

SECTION B – FEDERAL AWARD INFORMATION 15

1. ESTIMATE OF FUNDS AVAILABLE AND NUMBER OF AWARDS CONTEMPLATED 15

2. START DATE AND PERIOD OF PERFORMANCE FOR FEDERAL AWARDS 15

3. TYPE OF INSTRUMENT 15

4. AUTHORIZED GEOGRAPHIC CODE 16

5. NATURE OF THE RELATIONSHIP BETWEEN USAID AND THE RECIPIENT 16

SECTION C – ELIGIBILITY INFORMATION 17

1. ELIGIBILITY APPLICANTS 17

2. COST SHARING OR MATCHING 17

3. NUMBER OF SUBMISSION AS THE PRIME APPLICANT 17

4. EXCLUSIVITY 17

SECTION D – APPLICATION SUBMISSION INFORMATION 19

1. AGENCY POINT OF CONTACT (POC) 19

2. OVERVIEW OF THE APS PROCESS 19

3. UNIQUE ENTITY IDENTIFIER and SYSTEM for AWARD MANAGEMENT (SAM) 20

4. SUBMISSION DATES AND TIMES 21

5. FUNDING RESTRICTIONS 21

6. CONFLICT OF INTEREST PRE-AWARD TERM (ADS 303mba, Dated 08/30/2018) 21

7. OTHER SUBMISSION REQUIREMENT 22

SECTION E – APPLICATION REVIEW INFORMATION 23

SECTION F – FEDERAL AWARD ADMINISTRATION INFORMATION 24

1. FEDERAL AWARD NOTICES 24

2. ADMINISTRATIVE AND NATIONAL POLICY REQUIREMENTS 24

3. REPORTING REQUIREMENTS 25

4. PROGRAM INCOME 25

5. INITIAL ENVIRONMENTAL EXAMINATION 25

SECTION G – FEDERAL AWARDING AGENCY CONTACTS 26

1. APS POINTS OF CONTACT 26

2. ACQUISITION AND ASSISTANCE OMBUDSMAN 26

SECTION H – OTHER INFORMATION 27

ACRONYMS

ACF Active Case Finding

ADS Automated Directives System

AO Agreement Officer

AOR Agreement Officer’s Representative

APS Annual Program Statement

CDCS Country Development Cooperation Strategy

CFDA Catalog of Federal Domestic Assistance

CFR Code of Federal Regulations

DO Development Objective

DR TB Drug Resistant TB

FAA Federal Foreign Act

FAA Fixed Amount Award

GOI Government of Indonesia

HSS Health System Strengthening

MoH Ministry of Health

MDR TB Multidrug Resistant Tuberculosis

NGO Non-governmental Organization

NTP National Tuberculosis Program

OAA Office of Acquisition and Assistance

PoC Point of Contact

SDG Sustainable Development Goal

TB Tuberculosis

TPT TB preventive treatment

SECTION A – PROGRAM DESCRIPTION

This funding opportunity is authorized under the Foreign Assistance Act (FAA) of 1961, as amended. The resulting awards will be subject to 2 CFR 200 – Uniform Administrative

Requirements, Cost Principles, and Audit Requirements for Federal Awards, and USAID’s supplement, 2 CFR 700, as well as the additional requirements found in Section F of this APS.

A. BACKGROUND

While Indonesia has made progress over the past decade toward reducing Tuberculosis (TB) incidence and increasing treatment success rates, significant challenges to eliminating TB remain. In 2021, an estimated 969,000 people fell ill with TB in Indonesia and approximately

411 people died every day from the disease.1 Although case notifications (the number of cases identified and reported) slightly recovered from 384,025 in 2020 to 432,577 in 2021, notifications in 2021 continue to reflect less than half of TB cases.2 Consequently, many TB patients remained either undiagnosed or diagnosed but not notified to the National

Tuberculosis Program (NTP) making it harder to find and treat TB cases. Of the new cases diagnosed and started on care, 86 percent were successfully treated.3 However, in 2021, an estimated 28,000 patients still developed drug resistant TB (DR-TB)/MDR-TB, but only roughly

30% (8,268) of cases were diagnosed and only 63 percent of those cases were initiated on treatment.4 Meaning that drug resistant TB strains, which require longer treatment regimens and are more expensive to treat, are still spreading in Indonesia.

At the national level, the past few years have marked strong political commitment by the

Government of Indonesia to address the TB epidemic. In the first UN high-level meeting on

TB held in 2018, Indonesia reaffirmed the sustainable development goal (SDG) target to reduce the death rate from tuberculosis by 90% and reduce the incidence rate of tuberculosis by up to 80% by 2030. Additionally, Indonesia pledged support for global targets to treat 40 million people for TB and administer TB preventive treatment (TPT) to 30 million people by 2022. With political will, came increases in domestic funding for TB, which more than doubled from 53 million in 2017 to 109 million in 2019.5 Furthermore, the National

World Health Organization, Tuberculosis Profile: Indonesia, 202`1 data.

https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22ID%22 2 Ibid 3 Ibid 4 World Health Organization: Diagnosis, notification, and treatment of Rifampicin-Resistant TB (MDR-TB/RR-TB).

https://app.powerbi.com/view?r=eyJrIjoiZDhjNDM0YmMtOGExOS00ODIxLWEzMjktZDk0NmI4YTAwODgwIiwidCI6ImY2MTBjMGI3 LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9 5 “The Republic of Indonesia Joint External Monitoring Mission for Tuberculosis (JEMM), January 20-31,2020” (WHO, 2020)

Tuberculosis Program (NTP) housed within the Ministry of Health (MOH), made coordinated efforts to increase distribution of GeneXpert machines to improve TB diagnosis, developed a

TB Information System to improve TB recording and reporting, and standardized procedures and policies for TB programs at the national level. However, global progress is anticipated to fall short of achieving 2030 TB targets.6

In early 2020, the COVID-19 pandemic struck Indonesia, worsening national efforts in fighting

TB. As a result, progress on key TB indicators declined and Indonesia continues to grapple with the second highest burden of TB in the world. 7 To regain lost ground on TB, President Jokowi issued a decree to establish a multi-sectoral response to accelerate achievement of the 2030

TB elimination targets as current efforts are insufficient to achieve TB elimination.8

B. PROBLEM STATEMENT

More than 900,000 people continue to fall ill with TB in Indonesia every year and with the

COVID-19 pandemic TB notifications, treatment outcomes, and TPT uptake have further declined. Without concerted and collaborative efforts to accelerate the detection, treatment, and prevention of TB cases, Indonesia may not achieve its TB elimination targets by 2030.

Therefore, there is an urgent need to accelerate progress towards 2030 TB elimination targets in Indonesia. USAID seeks innovative and comprehensive solutions and strategies to collaboratively advance progress in TB control.

C. GOAL AND OBJECTIVES

Through the Accelerating Elimination of Tuberculosis in Indonesia Annual Program Statement

(APS), USAID intends to assist Indonesia in accelerating achievement toward its 2030 TB elimination targets by improving the quality of TB case detection, diagnosis, care, and prevention for all people affected by TB while also improving essential components of the health system. To achieve this goal, USAID will pursue seven main objectives in line with the

U.S. Government Global TB strategy 2015-20199 and the National Tuberculosis Strategy for

6 United Nations. (2021).Progress towards the achievement of global tuberculosis targets and implementation of the political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis

World Health Organization Global lists of high burden countries forTuberculosis (TB),TB/HIV, and Multidrug/Rifampicin Resistant TB (MDR-

TB/RR-TB), 2021-2025,

2021. https://cdn.who.int/media/docs/default-source/hq-tuberculosis/who_globalhbcliststb_2021-2025_backgrounddocument.pdf?sfvrsn= f6b854c2_9 8 To Realize The Elimination Of Tuberculosis 2030, Jokowi Issues Presidential Regulation On TB Control. https://voi.id/en/news/77813/to-realize-the-elimination-of-tuberculosis-2030-jokowi-issues-presidential-regulati on-on-tb-control 9 United States Government Global Tuberculosis Strategy, 2015-2019.

Tuberculosis Care and Prevention in Indonesia 2020-2024.10 By structuring the awards through an APS, USAID expects that the resulting agreements will include numerous new partnerships that expand opportunities to use innovative approaches to address the challenge of TB in

Indonesia.

Goal: To assist the Government of Indonesia in addressing the TB epidemic and achieving 2030

TB elimination targets.

Objectives:

1. Enhanced capacity for TB case finding

2. Improved quality of TB screening and diagnosis

3. Improved quality of TB service delivery

4. Prevention of TB optimized

5. Strong and resilient health system to accelerate TB elimination

6. Community participation in implementing development activities strengthened

7. Implementation research to improve TB control

D. ACTIVITY DESCRIPTION

The End TB strategy highlights the fundamental need to ensure early diagnosis and treatment of patients with effective and uninterrupted anti-TB drugs. However, during the COVID-19 pandemic, TB notifications declined by 31%11 in Indonesia. With the Accelerating Elimination of

Tuberculosis in Indonesia APS, USAID/Indonesia is planning to comprehensively address key challenges in the national TB program and provide targeted support for national TB priorities, which will result in significant improvement in TB case detection, treatment initiation, and treatment completion, while also improving the sustainability and resilience of the TB program at the national and provincial/district levels. This will require delivery of equitable TB services that take into account people-centered and cost-effective approaches that address major barriers to accessing quality TB services that are inclusive, combat stigma and discrimination, address gender related challenges, and promote innovative approaches to improve TB control.

Activities under the Accelerating Elimination of Tuberculosis in Indonesia APS will aim to fulfill the goal by contributing to one or more of the program’s seven objectives.

1. Enhanced capacity for TB case finding

10 Strategi Penanggulangan Tuberkulosis di Indonesia 2020-2024, Kementerian Kesehatan Republik Indonesia, 2020 11WHO Global Tuberculosis Report 2021

Substantial gaps between the estimated TB incidence and case notifications have resulted in a considerable proportion of missing TB cases in Indonesia. Exclusively relying on passive case finding is insufficient to detect TB patients who do not seek care at health facilities.

Additionally, several behavioral and societal factors contribute to poor case detection among women. This includes inability to access services due to financial barriers and stigma from community members. Furthermore, while women globally tend to seek care earlier than men do, they often delay diagnosis and treatment longer suggesting that tailored programing must be put in place to address the issue.

Limited access to services for vulnerable populations, such as children, residents living in urban slums, and those in remote areas pose additional challenges to TB case finding. Furthermore, the absence of active efforts to reach vulnerable populations hinders acceleration of early case detection and increases risk of transmission to larger communities, leading to unfavorable outcomes. The global TB community consistently promotes Active Case Finding (ACF) to identify

TB cases beyond or outside of health facilities. A few small scale ACF interventions have been implemented in different settings in Indonesia but introducing an innovative approach to ACF that is tailored to Indonesia's varied geographical and cultural context remains important.

USAID’s gender analysis recommends that it is important to have strategies in enabling TB case finding among vulnerable groups in urban and hard- to- reach areas. This focus, however, will need to be developed in addition to but not as a replacement of cost-effective facility-based interventions to systematically find and link TB cases to care. Additionally, supporting ongoing activities to investigate TB exposure among close contacts of active TB patients through contact investigation remains essential. This includes conducting contact investigation in congregate settings with high TB transmission risk, such as workplaces, mines, boarding schools, and etc.

This initiative would also be key to respond to persistent challenges in finding childhood TB cases in Indonesia. Additionally, assistance in pursuing an integrated model of TB case finding with other health priorities to ensure early diagnosis and continuity of care requires more focused attention.

2. Improved quality of TB screening and diagnosis

Global policies require universal access to rapid diagnostic tests for all new and relapse TB patients. Typically, patients are diagnosed after they show signs of symptoms, however this could result in delayed diagnosis as according to the latest TB Prevalence Survey, as many as

40%12 of those with bacteriologically confirmed TB in Indonesia do not have specific TB

12 Indonesia TB Prevalence Survey, 2014 symptoms. Therefore, there is a need for effective screening tools and strategies to identify asymptomatic TB. Furthermore, men have a higher burden of disease, leading to a reported 2.3 male-to-female ratio for bacteriologically confirmed adult TB cases. However, despite having more TB cases among men, men are very often missing from the TB continuum of care, thus a specific approach is needed to ensure effective screening practices and strategies are designed and tailored to men.

Due to low bacilli counts and difficulties detecting TB bacteria in children, special attention is also needed to improve existing and to introduce new diagnostic tools. Improving TB diagnostics and screening for all patients will require a reliable, well-organized, and effectively operated diagnostic network that involves all levels of the TB laboratory hierarchy and ensures a strong quality assurance system is in place. The main focus of the response to the aforementioned challenges should be improving the availability of feasible and scalable diagnostic approaches across the full spectrum of TB care and the health system.

In addition to identifying people with active TB disease, Indonesia’s NSP has set ambitious goals to improve TB preventive treatment (TPT) coverage, and for that reason TB infection testing remains a priority. To respond to this challenge, more efforts should be made to introduce and adopt existing and novel TB infection diagnostic tools, methods, and techniques.

3. Improved quality of TB service delivery

Recognizing the significant need for applying a patient-centered model in achieving universal access to quality TB care in all sectors (both public and private), USAID envisions leveraging the use of digital adherence monitoring tools, provision of social and psychological support, and provision of mental health counseling to TB patients.

Continued efforts to promote private sector engagement also remains essential for Indonesia’s

TB program. Future private sector engagement in TB should explore the opportunity to leverage the private sector’s potential to deliver integrated DS- and DR-TB care. At the same time, it is important to strengthen the quality of healthcare in the public sector by integrating

TB care across other related health priorities.

Despite innovations in DR-TB diagnosis and treatment over the past decade, addressing DR-TB in Indonesia remains a challenge. Over the past several years, a number of essential programmatic gaps have persisted such as high rates of initial lost-to-follow up, poor treatment adherence, and low treatment success rates for both adults and children. Furthermore, negative stigma associated with TB as well as the lack of necessary legal identity documents to access health services or to enroll in health insurance for Key Affected Populations (KAPs) and

Persons with a Disability, are additional barriers to TB testing and treatment. This signifies the urgent need to improve the quality of DR-TB management, including but not limited to the scalable uptake and introduction of novel short-all oral regimens to increase treatment coverage while improving treatment results for all TB patients and promoting patient-centered care as the fundamental principle in managing TB care.

4. Prevention of TB optimized

Effective management of TB Infection is essential to control the TB epidemic and prevent TB infection from progressing to active disease. Timely and appropriate TB prevention along with contact investigation should be a fundamental part of a national activity targeting screening of people who are at high risk for developing TB in the community, and other settings such as workplaces, prisons, and religious boarding schools to address the underlying clinical and risk factors for TB progression. For people with high-risk of developing active TB disease, provision of novel, short-course TPT regimens is crucial.

There is a need to support a broader range of prevention activities, including: strengthening targeted screening for active TB among high-risk individuals and groups, including healthcare workers; improving infection control interventions to prevent transmission in healthcare facilities and other congregate settings; and screening for and treatment of TBI to reduce the risk of progression to active TB among individuals with or at greatest risk to develop TB.

For the above purposes, a strong strategy for the development and dissemination of information and education on TB prevention and care has to be in place for use across all sectors.

Ending TB calls for innovative tools and strategies over the whole TB cascade, e.g., sensitive diagnostic tools, the most effective regimens for treating TB, and efficacious TB vaccines. At the global level, several potential vaccine candidates against TB are currently under development, and there is increasing confidence that a new TB vaccine will become available in the coming years. It will be important to anticipate this promising lifesaving approach, ensuring Indonesia's readiness in adopting and deploying a new TB vaccine.

5. Strong and resilient health system to accelerate TB elimination

USAID recognizes that both specific disease programs and larger health initiatives could benefit from a strong and resilient health system. USAID’s TB activities will translate this Health System

Strengthening vision (HSS) into sustainable strategies towards achieving the desired intermediate results of equity, quality, and resources optimization. For this purpose, strategic yet practical approaches are needed to strengthen the National TB Program’s capacity to meet those three intermediate outcomes across the traditional elements of HSS: service delivery, human resources, health information systems, access to essential medicines, and financing and governance. This will eventually lead to improved performance of the health system, which will advance TB elimination.

Successful TB management requires strengthening of the entire health system, which includes ensuring there is a strong system in forecasting, procurement, and supply chains for TB drugs and commodities; existence of a national health information system that effectively and efficiently records and reports TB cases and related deaths; utilization of information generated by the system to inform decision making at all levels; improvement in mobilizing, distributing, and building up the capacity of dedicated human resources in the TB program, especially at the primary health care level, where providers spearhead TB services in Indonesia; and sustaining funding for reducing the TB burden.

Robust HSS also requires the ability to rapidly respond to the emerging and acute crises that significantly threaten the country's efforts in combating TB. The COVID-19 pandemic generated mounting evidence that the co-occurrence of prominent diseases has a profound effect on worsening TB outcomes. Understanding that the dynamic health security context at both the global and country levels have the potential to severely disrupt TB programs, a resilient health system is vital. The country must have the flexibility to adapt and adjust policies and resources to respond to disease threats, while maintaining the system’s functionality in delivering quality

TB service and meeting the 2030 TB elimination targets.

All of the above are key elements that must be considered to meet the needs of diverse communities at risk. This requires execution of strategic interventions that address major barriers to rapid adoption of the global and national TB strategies, development and implementation of evidence-informed policy, bolder multi-sectoral commitment in TB prevention and care, service uptake by communities at greater risk of TB, and social inclusion in

TB case management.

In order to support the government of Indonesia in implementing gender responsive TB prevention and care across the health system, the activity will improve gender awareness among stakeholders through gender integration workshops, so the TB programs are tailored to the specific needs of different genders and so that everyone has equal access to and benefit from TB services. In Indonesia, District health offices are responsible for developing yearly program plans, with support for budget planning from regional and national level planning agencies. Improving gender awareness among these stakeholders can increase their awareness on how to use gender lens in program planning and implementation can help them better respond to local gender-related TB needs.

6. Community participation in implementing development activities strengthened

A successful TB program requires both the government and community to actively take responsibility in planning, implementing, and monitoring TB control activities. USAID envisages greater engagement of the community in TB programs beyond their traditional role as the primary beneficiaries. Communities must be involved in shaping policy on patient-centered programs, delivering quality community-based TB care, and advancing the community’s potential in other TB management roles. By acknowledging the fundamental role of the community, USAID recognizes that stronger partnership and collaboration between key TB stakeholders and communities is imperative. Activities will need to support regulation and resources for broader community involvement in TB programs and combat challenges. For example, women’s lesser inclusion due to traditional gender roles that assign women to household labor and caregiving duties that may prevent them from participating in community engagement activities are among key concerns.

In line with the USAID Local Capacity Strengthening Policy, this activity will support and work in partnership with local actors and networks to lead achievement of their own development goals. The activity will work with local partners to provide capacity strengthening support that is tailored to the Indonesian context and reflects local partners desires and needs. While the support provided through this activity will improve the ability of local organizations, including those representing vulnerable groups, to lead USAID-funded projects, the ultimate goal is to improve these organizations capabilities to implement development activities as a whole beyond USAID. This includes improving organizations capacity in areas such as gender-responsive TB programming, organizational, and financial management. This activity will also promote various approaches such as improving the capability of organizations to access local government budgets and other budget sources at the sub-national level, as well as leveraging private sector funding/co-investment in Indonesia.

7. TB implementation research to improve TB control

Operational research provides the required evidence-based knowledge to support NTP in planning and rolling out strategic interventions in an efficient manner, which is important to meet TB targets. Although operational research has been more frequently undertaken in

Indonesia in the past few years, little is known about its expected impact on the broader TB control program. To meet 2030 TB elimination targets, TB control activities need to be available across the country and operate at high standards. This is where the operational research role comes in as a guide for improving TB program performance through proven problem-solving approaches or by adding new knowledge to the TB field. Therefore, it is important to ensure that identified gaps in delivering TB control programs are addressed through reliable strategies, namely those resulting from relevant but feasible operational research that results in greater use of OR to inform NTP policy and the scale up of evidenced-based interventions within the

Indonesia context, including but not limited to minimizing the gap in data availability for how women and disadvantaged groups participate in health systems and access needed health services and information, as well as gender data on treatment coverage.

Expected Results:

The Accelerating Elimination of Tuberculosis in Indonesia APS aims to contribute to an overall decline in TB incidence, prevalence, and mortality in Indonesia. Specific expected results will be described in each addendum issued under the APS.

E. GEOGRAPHIC FOCUS

The proposed geographic locations for this APS are North Sumatra, Banten, DKI Jakarta, West

Java, Central Java, East Java, and South Sulawesi provinces. The selections are based on the highest TB burden provinces and prioritized within the eight priority provinces under USAID’s

Country Development Cooperation Strategy (CDCS) 2020-2025. The Activity will work in at least

50% of the number of districts based on its TB burden in the seven provinces above. The

Activity will finalize the geographic locations based on available and upcoming data in consultations with MOH and selected regional governments (PHOs and DHOs). The map below shows the proposed provinces for the APS, the CDCS priority provinces, and the estimated TB cases per province in 2019.

[End of this Section]

SECTION B – FEDERAL AWARD INFORMATION

Issuance of this APS and its related APS Addendum do not constitute an award commitment on the part of the USG, nor do those commit the USG to pay for any costs incurred in the preparation and/or submission of questions, comments, suggestions, concepts and/or full applications. Applicants submit their applications at their own risk, and all preparation and submission costs are at their expense.

Applicants must provide concepts in response to, and in accordance with the instructions provided in a specific Addendum to this APS. Specific information and instructions for concepts submission under this APS will appear in the individual APS Addendum. The APS Addendum will be exclusive source of funding through this APS and will be posted on www.grants.gov

1. ESTIMATE OF FUNDS AVAILABLE AND NUMBER OF AWARDS CONTEMPLATED

This APS is not supported by specific funds information. This APS represents the framework through which funded APS Addendums issued under this APS will be constructed. USAID reserves the right to make or not make awards through this APS. The actual number of assistance awards, if any, under this APS is subject to the availability of funds, as well as the viability of eventual applications received. Individual APS Addendums issued under this APS will specify the estimated funding available and the number of awards contemplated.

2. START DATE AND PERIOD OF PERFORMANCE FOR FEDERAL AWARDS

The actual period of performance for each issued award as a result of this APS will be based on the negotiated start date or as determined later during the selection process such as during co-creation, and subject to availability of funds.

3. TYPE OF INSTRUMENT

Awards that result from this APS may take the form of a grant or a cooperative agreement. If the award of a cooperative agreement is anticipated, the expected USAID substantial involvement will be described in the Addendum or communicated later during the selection process. Further, USAID will make a determination on the intended substantial involvement by the Agency, and thereby the type of award(s), after the co-creation process, depending on the results of this process.

4. AUTHORIZED GEOGRAPHIC CODE

The geographic code for the procurement of commodities and services under this program is

937. If there is a need to utilize geographic code 935, a waiver in compliance with 22 CFR 228 will be prepared prior to the APS Addendum document being released.

5. NATURE OF THE RELATIONSHIP BETWEEN USAID AND THE RECIPIENT

The principal purpose of the relationship with the Recipient and under the subject program is to transfer funds to accomplish a public purpose of support related to the objectives outlined in the Accelerating Elimination of TB in Indonesia’s Program Description which is authorized by

Federal Statute. The successful Recipient will be responsible for ensuring the achievement of the program objectives and the efficient and effective administration of the award through the application of sound management practices. The Recipient will assume responsibility for administering Federal funds in a manner consistent with underlying agreements, program objectives, and the terms and conditions of the Federal award.

SECTION C – ELIGIBILITY INFORMATION

1. ELIGIBILITY APPLICANTS

Eligibility will be further described in each APS Addendum(s). Further, the organization must be a legally-recognized, organizational entity under applicable law, legally registered in a country within the geographic code 937 (“the United States, the recipient country, and developing countries other than advance developing countries, but excluding any country that is a prohibited source,” per ADS 310.3.1.1).

The Agreement Officer may determine a Pre-Award survey is required and if so, would establish a formal survey team to conduct an examination that will determine whether the prospective recipient has the necessary organization, experience, accounting and operational control, and technical skills - or ability to obtain them - in order to achieve the objectives of the program.

Further, while for-profit firms may participate, pursuant to 2 CFR 200.400(g) it is USAID’s policy not to award profit to prime recipients and subrecipients under assistance instruments.

However, while profit is not allowed for sub-awards, the prohibition does not apply when the recipient acquires goods and services in accordance with 2 CFR 200.317-326, “Procurement

Standards”. This is also discussed more specifically in ADS 303sai “Profit Under USAID

Assistance Instruments”.

2. COST SHARING OR MATCHING

There are no cost share requirements for awards issued under this APS. If there is any cost share requirement, it will be further described in each APS Addendum(s).

3. NUMBER OF SUBMISSION AS THE PRIME APPLICANT

Unless otherwise specified in Addendum, all interested organizations are restricted to submitting only one concept per Addendum as the Prime Applicant. Please note that organizations can serve as sub-awardees or supporting partners on multiple concepts under an

Addendum.

4. EXCLUSIVITY

To maximize the number of competitive applications, prime applicants must not enter into exclusivity agreements with proposed sub-awardees. In other words, sub-awardees must be allowed to be listed on multiple applications by multiple applicants as they choose. Exclusivity agreements between the prime applicant and proposed key personnel are also not required.

SECTION D – APPLICATION SUBMISSION INFORMATION

1. AGENCY POINT OF CONTACT (POC)

The Agency POC for this umbrella APS are:

a. Mr. Mohib Ahmed

Supervisory Agreements Officer

b. Ms. Yulian Christanti

A&A Specialist

Office of Acquisition and Assistance (OAA)

USAID Indonesia

Email at applications-indonesia@usaid.gov with a copy to ychristanti@usaid.gov

Applicants are reminded to follow the instruction provided in each APS Addendum; each

Addendum may provide a different Agency POC.

2. OVERVIEW OF THE APS PROCESS

a. Questions and Answers

Questions regarding this umbrella APS must be submitted in writing via email with a subject line of “Question - Umbrella APS No. 72049723APS00001” by the closing date indicated in the cover letter. Any information given to prospective applicants concerning this APS will be furnished promptly to all other prospective applicants as an amendment to this APS if that information is necessary in submitting applications or if the lack of it would be prejudicial to any other prospective applicant.

Questions regarding a specific APS Addendum, must be submitted to the point of contact listed in that Addendum.

b. Application Content and Process

This APS will be opened for the period mentioned in the cover page. Following this APS, the mission will issue APS Addendum(s). Detailed information and instruction including the requirement to submit an application will be available in the APS Addendum(s).

mailto:applications-indonesia@usaid.gov mailto:ychristanti@usaid.gov

Applicants must submit only the information and materials requested and in the format specified in each APS Addendum(s). Each APS Addendum may contain different requirements and instructions.

3. UNIQUE ENTITY IDENTIFIER and SYSTEM for AWARD MANAGEMENT (SAM)

USAID reserves the right to make no award under this APS or any APS Addendum at any stage of the process. If requested to submit a full application, the applicant(s) is required to:

a. Be registered in SAM (System for Award Management) before submitting its application;

b. Provide a valid Unique Entity Identifier (UEI) number in its application; and

c. Continue to maintain an active SAM registration with current information at all times during which it has an active Federal award or an application or plan under consideration by a Federal awarding agency.

USAID will not make or issue any award to an applicant until the applicant has complied with all applicable UEI and SAM requirements and, if an applicant has not fully complied with the requirements by the time USAID is ready to make an award, USAID may determine that the applicant is not qualified to receive a Federal award and use that determination as a basis for making a Federal award to another applicant.

Per 2 CFR Appendix I to Part 200, Full Text of the Notice of Funding Opportunity, Section E.3, USAID hereby informs all potential applicants:

“i. That the Federal awarding agency, prior to making a Federal award with a total amount of Federal share greater than the simplified acquisition threshold, is required to review and consider any information about the applicant that is in the designated integrity and performance system accessible through SAM (currently FAPIIS) (see 41 U.S.C. 2313);

ii. That an applicant, at its option, may review information in the designated integrity and performance systems accessible through SAM and comment on any information about itself that a Federal awarding agency previously entered and is currently in the designated integrity and performance system accessible through SAM;

iii. That the Federal awarding agency will consider any comments by the applicant, in addition to the other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in § 200.206.”

https://www.govinfo.gov/link/uscode/41/2313 https://www.govinfo.gov/link/uscode/41/2313 https://www.ecfr.gov/current/title-2/section-200.206 https://www.ecfr.gov/current/title-2/section-200.206

4. SUBMISSION DATES AND TIMES

Each APS Addendum will indicate due dates and times for all submissions, including any other submissions of information, for example concept paper.

5. FUNDING RESTRICTIONS

● Construction is not an allowable activity under this APS. Relevant risk assessments must be completed before the awardee(s) can incur costs for any minor renovation work that does not qualify as construction.

● USAID does not allow reimbursement of pre-award costs under any round(s)/

Addendum(s) of this APS.

● Profit is not allowable for recipients or subrecipients under any resulting award(s) made under this APS.

● Except as may be specifically approved in advance by the Agreement Officer, all commodities and services that will be reimbursed by USAID under any resulting awards under this APS must be from the authorized geographic code specified in Section B of this APS unless a different geographic code is otherwise authorized by USAID, and must meet the source and nationality requirements set forth in 22 CFR 228.

6. CONFLICT OF INTEREST PRE-AWARD TERM (ADS 303mba, Dated 08/30/2018)

a. PERSONAL CONFLICT OF INTEREST

(1) An actual or appearance of a conflict of interest exists when an applicant organization or an employee of the organization has a relationship with an Agency official involved in the competitive award decision-making process that could affect that Agency official’s impartiality. The term “conflict of interest” includes situations in which financial or other personal considerations may compromise, or have the appearance of compromising, the obligations and duties of a USAID employee or recipient employee.

(2) The applicant must provide conflict of interest disclosures when it submits an SF-

424. Should the applicant discover a previously undisclosed conflict of interest after submitting the application, the applicant must disclose the conflict of interest to the Agreement Officer no later than ten (10) calendar days following discovery.

b. ORGANIZATIONAL CONFLICT OF INTEREST

The applicant must notify USAID of any actual or potential conflict of interest that they are aware of that may provide the applicant with an unfair competitive advantage in competing for this financial assistance award. Examples of an unfair competitive advantage include but are not limited to situations in which an applicant or the applicant’s employee gained access to non-public information regarding a federal assistance funding opportunity, or an applicant or applicant’s employee was substantially involved in the preparation of a federal assistance funding opportunity.

USAID will promptly take appropriate action upon receiving any such notification from the applicant.

7. OTHER SUBMISSION REQUIREMENT

Each APS Addendum or request for full applications will include the following pre-award terms, as applicable: [ADS 303mba Pre-Award Terms]

● Branding Strategy - Assistance

● Marking Plan - Assistance

SECTION E – APPLICATION REVIEW INFORMATION

This APS does not provide merit review information. Interested Applicants should find the merit review information in each APS Addendum(s). All submissions received by the deadline stated on the cover page of each APS Addendum or its amendment, will be reviewed for eligibility and compliance with the instructions for submission prior to evaluation against the merit review criteria. The AO will forward to the Selection Committee (SC) those submissions that are complete and comply with the instructions. The SC then conducts a merit review and provides recommendation to the AO. Any submissions received after the deadline will not be accepted.

The final selection of the successful applicant will be determined by the AO.

SECTION F – FEDERAL AWARD ADMINISTRATION INFORMATION

1. FEDERAL AWARD NOTICES

Award of the agreement contemplated by this APS cannot be made until funds have been appropriated, allocated, and committed through internal USAID procedures. While USAID anticipates that these procedures will be successfully completed, potential applicants are hereby notified of these requirements and conditions for the award.

Notifications to Unsuccessful Applicants

a. Concept Papers: Once USAID decides which applicant(s) will be requested to submit a full application, USAID will notify all unsuccessful applicants that their concepts were not accepted, and that a full application is not requested and will not be considered.

b. Full Applications: Once USAID decides which applicant(s) will not be considered for an award(s), USAID will notify all such unsuccessful applicants that they will not be considered further and briefly explain why USAID did not select their application.

Within 10 working days after an unsuccessful applicant receives notice that USAID will not fund its application, the unsuccessful applicant may send a written request for additional information, in accordance with ADS 303.3.7.2 Request for Additional

Information.

2. ADMINISTRATIVE AND NATIONAL POLICY REQUIREMENTS

Any resulting award(s) from this APS will be administered in accordance with relevant policies and regulations, depending on the type of recipient organization, type of award, and any other relevant factors.

For U.S. NGOs:

● ADS Chapter 303

● 2 CFR 200

● 2 CFR 700

● ADS 303maa, Standard Provisions for US Nongovernmental Organizations.

For Local NGOs:

● ADS 303mab, Standard Provisions for Non-US Nongovernmental Organizations.

For Fixed Amount Awards to NGOs:

● ADS 303mat, Standard Provisions for FAA to NGOs

For Public International Organizations (PIOs):

● ADS Chapter 308

3. REPORTING REQUIREMENTS

Reporting requirements will be specified in each APS Addendum or will be determined later as part of the co-creation process or in a request for full application. USAID anticipates that program implementation reporting will be determined based on the outcome of the collaborative co-creation process, and that an annual performance monitoring and evaluation plan, using established baseline data and specific, measurable targets and indicators will also be agreed upon.

4. PROGRAM INCOME

Program income may be generated under awards resulting from this APS. If program income is anticipated to be earned under an award, the Agreement Officer will determine the most appropriate use of such program income and will specify in the award how such program income will be treated. This may include applying one of the three approaches (deduction, addition, or cost-sharing) described at 2 CFR 200.307(e); also refer to Required as Applicable

Provision “Program Income” in ADS 303 for non-US NGOs. If the program income is to be utilized in a different way, the APS Addendum will include this information. It must be used in a manner allowable under the CFR and ADS references above.

5. INITIAL ENVIRONMENTAL EXAMINATION

In accordance with 22 CFR 216.3(a)(7)(iv), USAID/Indonesia has deferred a threshold determination for this APS, with concurrence from the Bureau Environmental Officer, until the post-award stage. The designated AOR will work with the Mission Environmental Officer (MEO) to complete all environmental-compliance documentation in a timely manner prior to any major implementation.

SECTION G – FEDERAL AWARDING AGENCY CONTACTS

1. APS POINTS OF CONTACT

Federal awarding agency points of contact (POC) will be specified in each APS Addendum(s).

2. ACQUISITION AND ASSISTANCE OMBUDSMAN

The A&A Ombudsman helps ensure equitable treatment of all parties who participate in

USAID’s acquisition and assistance process. The A&A Ombudsman serves as a resource for all organizations who are doing or wish to do business with USAID. Please visit this page for additional information: https://www.usaid.gov/work-usaid/acquisition-assistance-ombudsman

The A&A Ombudsman may be contacted via: ombudsman@usaid.gov https://www.usaid.gov/work-usaid/acquisition-assistance-ombudsman mailto:ombudsman@usaid.gov

SECTION H – OTHER INFORMATION

USAID reserves the right to fund any, portions of, or none of the concepts/full applications submitted under Addendum to this APS.

The Agreement Officer is the only individual who may legally commit the Government to the expenditure of public funds. Any award and subsequent incremental funding will be subject to the availability of funds and continued relevance to Agency programming.

Applications with Proprietary Data

Applicants who include data that they do not want disclosed to the public for any purpose or used by the U.S. Government except for evaluation purpose, should mark the cover page with the following:

“This application includes data that must not be disclosed, duplicated, used, or disclosed - in whole or in part - for any purpose other than to evaluate this application. If, however, an award is made as a result of - or in connection with - the submission of this data, the U.S.

Government will have the right to duplicate, use, or disclose the data to the extent provided in the resulting award. This restriction does not limit the U.S. Government’s right to use information contained in this data if it is obtained from another source without restriction. The data subject to this restriction are contained in sheets [insert sheet numbers].”

Additionally, the applicant must mark each sheet of data it wishes to restrict with the following:

“Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this application.”